TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Vera Therapeutics
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Vera Therapeutics submitted a Biologics License Application to the FDA for atacicept, a potential treatment for IgA Nephropathy, after successful Phase 3 trial results showing significant proteinuria reduction. The drug targets B-cell cytokines and could potentially be approved in 2026.

Insights
NKE   neutral

Mentioned as a traditional competitor in sports merchandising, with lower margins compared to Lululemon


VERA   positive

Company achieved significant clinical trial results, submitted BLA, and is advancing a potentially breakthrough treatment for a serious kidney disease